Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations

Roberta Riccioni, Elvira Pelosi, Viviana Riti, Germana Castelli, Francesco Lo-Coco, Ugo Testa

Research output: Contribution to journalArticlepeer-review


FMS-related tyrosine kinase 3 (FLT3) mutations are found in 30% of cases of acute myeloid leukaemia (AML). In addition, recent studies have lead to the identification of about 10-15% of AML patients displaying high expression of FLT3, not associated with mutations of the receptor (FLT3 Wild-type High, FLT3WTH). These AMLs, as well as those displaying internal tandem duplication (ITD) are associated with an unfavourable prognosis. However, the biological features of these AMLs are poorly characterized. The present study explored the immunophenotypic features of FLT3WTH AMLs in 94 de novo cases of AML. The levels of FLT3 expression, as assessed by flow cytometry and FLT3 mutational status, was used to identify four AML subgroups: FLT3WTH (14/94); FLT3 Wild-type low (FLT3WTL, 48/94); FLT3 internal tandem duplication (FLT3ITD 26/94); FLT3 aspartic acid 835 (FLT3D835, 6/94). FLT3WTH and FLT3ITD were characterized by: high white blast cell counts; predominance of M4 and M5 French-American-British classification subtypes and associated expression of myelo-monocytic markers; high expression of CD123 and TRAIL-Rs; high expression of receptors for angiogenic growth factors. Addition of FLT3 Ligand to human CD34 + or monocytic cells stimulated CD123 and TRAIL-R expression. These findings are of potential value for the development of new therapeutic strategies.

Original languageEnglish
Pages (from-to)33-42
Number of pages10
JournalBritish Journal of Haematology
Issue number1
Publication statusPublished - Apr 2011


  • Acute myeloid leukaemia
  • FMS-related tyrosine kinase 3 mutations
  • Immunophenotype
  • Trail
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations'. Together they form a unique fingerprint.

Cite this